Winship Cancer Institute Cancer Center Support Grant

项目摘要/摘要 埃默里大学温希普癌症研究所(Winship)是佐治亚州唯一由NCI指定的癌症中心， 它现在是人口第八多的州，在密西西比河以东的州中拥有最大的土地面积 河。作为该州主要的第三级癌症护理和癌症研究机构，Winship致力于其 四个研究方案，由其六个共享资源支持，以应对相关的具体挑战 佐治亚州的癌症负担。这些挑战包括：高烟草使用率和烟草发病率-- 相关癌症；高比例的癌症患者是非裔美国人或黑人和/或有显著 他们在护理、预后和/或结果方面存在癌症差异问题；以及健康知识水平低。Winship的使命 是减轻佐治亚州公民的癌症负担，佐治亚州是其主要集水区。这将会实现的 通过：(1)寻求对癌症的分子、遗传和表观遗传学基础的更深入的了解；(2)发现新的 推动癌症检测、预防和/或治疗进步的知识；(3)开发或定义 作为更好的癌症治疗途径的新治疗靶点和/或药物；以及(4)研究和 实施以人口为基础的战略，减轻该州的癌症负担。164型Winship Core 成员积极参与Winship的四个研究项目之一，所有这些项目都有很强的重点 跨学科研究：癌细胞生物学、癌症遗传学和表观遗传学、癌症预防和 控制，以及发现和发展治疗学。Winship的成员由六个共享成员支持 资源：生物统计学和生物信息学共享资源，肿瘤动物模型共享资源，癌症 组织和病理学共享资源，Emory集成基因组学共享资源，Emory集成 蛋白质组学共享资源和集成成像共享资源；以及两个开发中的共享 资源：Winship研究信息学和干预开发、传播和实施 发展共享资源。Winship成员目前总共得到8480万美元的研究资金支持 (截至2016年3月31日)由埃默里大学颁发。Winship成员Curran和Bruner担任两个NCI的PI 授予NRG肿瘤学基金会总计2560万美元，以支持临床研究基础设施。 Winship的干预性和非干预性试验的患者登记人数继续增加，尤其是 来自代表不足的少数群体的患者，这些活动为FDA- 在目前的资助期内批准几种新型抗癌药物。Winship拥有杰出的 机构承诺，承诺在未来五年内提供2亿多美元的机构支持， 这一水平几乎是2011年的两倍。Winship享有相同的报告体系和组织地位 作为埃默里的医学、公共卫生和护理学院。Winship处于独特的地位，可以应用其科学 优势、出色的成员资格、强大的基础设施、强大的机构支持和全面的 培训计划，以履行其使命，减轻癌症对佐治亚州和其他州的负担。

PROJECT SUMMARY/ABSTRACT The Winship Cancer Institute of Emory University (Winship) is the only NCI-designated cancer center in Georgia, which is now the eighth most populous state and has the largest land area among states east of the Mississippi River. As the main tertiary cancer care and cancer research institution in the state, Winship has committed its four research programs as supported by its six shared resources to address the specific challenges associated with the cancer burden in Georgia. These challenges include: high tobacco usage and incidence of tobacco- related cancers; high proportion of cancer patients who are African American or black and/or have significant cancer disparity issues in their care, prognosis, and/or outcome; and low health literacy levels. Winship's mission is to lessen the burden of cancer for the citizens of Georgia, its primary catchment area. This will be accomplished by: (1) seeking greater insights into the molecular, genetic, and epigenetic basis of cancer; (2) discovering new knowledge that drives improvements in cancer detection, prevention, and/or therapy; (3) developing or defining novel therapeutic targets and/or agents as a pathway to better cancer therapies; and (4) studying and implementing population-based strategies to lessen the cancer burden in the state. The 164 Winship core members are actively engaged in one of four Winship research programs, all of which have a strong emphasis on transdisciplinary research: Cancer Cell Biology, Cancer Genetics and Epigenetics, Cancer Prevention and Control, and Discovery and Developmental Therapeutics. Winship's members are supported by six shared resources: Biostatistics and Bioinformatics Shared Resource, Cancer Animal Models Shared Resource, Cancer Tissue and Pathology Shared Resource, Emory Integrated Genomics Shared Resource, Emory Integrated Proteomics Shared Resource, and the Integrated Imaging Shared Resource; and two developing shared resources: Winship Research Informatics and Intervention Development, Dissemination, and Implementation Developing Shared Resources. Winship members are currently supported by $84.8M in total research funding (as of 3/31/2016) awarded via Emory University. Winship members Curran and Bruner serve as PIs on two NCI awards to the NRG Oncology Foundation for a total of $25.6M in support of clinical research infrastructure. Patient enrollment in Winship's interventional and non-interventional trials continues to increase, especially among patients from under-represented minority groups, and these activities have contributed to the FDA- approval of several novel anti-cancer agents during the present funding period. Winship has outstanding institutional commitment, with more than $200 million in institutional support committed over the next five years, a level almost twice that committed in 2011. Winship enjoys the same reporting line and organizational position as Emory's schools of medicine, public health, and nursing. Winship is uniquely positioned to apply its scientific strengths, outstanding membership, robust infrastructure, strong institutional support, and comprehensive training programs to fulfill its mission of lessening the burden of cancer on the state of Georgia and beyond.